To achieve an optimal effect, STING agonists must efficiently target the intrinsic STING of cancer cells, eliminate disseminated cancer cells, and inhibit recurrence during the inert stage of NSCLC metastasis, which involves not only STING in NSCLC cancer cells but also NK, CD4+ T, and CD8+ T cells [34]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.